AstraZeneca India Launches Eculizumab for Treating aHUS and PNH After CDSCO Approval

AstraZeneca India has introduced Eculizumab, a concentrate solution for infusion (300 mg, 10 mg/ml), to the Indian market. The medication is designed to treat two rare and life-threatening blood disorders: atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). The company received approval for the drug from the Central Drugs Standard Control Organisation (CDSCO), enabling its launch in India.

Eculizumab is an advanced therapy that targets specific pathways involved in these conditions. aHUS is characterized by abnormal blood clotting in small blood vessels, which can lead to organ damage, while PNH involves the destruction of red blood cells due to a genetic mutation. AstraZeneca’s introduction of this treatment aims to address critical gaps in managing these disorders within the country.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: September 9, 2025

Related posts:

Biopharmaceutical Companies Use Freedom to Operate Analysis to Mitigate Patent Infringement Risks World Health Assembly Focuses on Pandemic Preparedness and Universal Health Coverage Amid Absence of Top Financial Contributor Pharmaceutical Industry Adopts Advanced Manufacturing and Real-Time Data to Address Drug Shortages University of Otago Researchers Investigate Drug Resistance Mechanisms in Tuberculosis

Author

Mark Chiang